The biopharma ecosystem is back to full health. The first quarter of 2026 delivered one of the strongest quarters of biopharma M&A in recent years, fueled by a surge in $1B+ acquisitions as the accelerated dealmaking momentum from the second half of 2025 continued. Pharmaceutical and life sciences (PLS) dealmakers entered the year with strategies focused on three plays: replenishing late-stage pipelines ahead of looming loss-of-exclusivity (LOE) cliffs; strengthening their competitive edge in high growth therapeutic areas such as cardiometabolic, immunology, oncology, and radiopharmaceuticals; and deploying dry powder while biotech valuations are rebounding.
Read the full article: PwC: Pharmaceutical and Life Sciences – US Deals 2026 Midyear Outlook //
Source: https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html